Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 193 + IDE397 in Advanced MTAP-null Solid Tumors
2023-504364-42-00Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of anvumetostat and IDE397 in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by Amgen. Primary endpoints: Part 1: Dose-limiting toxicities and safety profile and Part 2: Objective response rate by RECIST v1.1. Started Jul 2024; status: completed.
02
Drugs
anvumetostatIDE397
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504364-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504364-42-00.